Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224924 · ClinicalTrials.gov registry record · Phase 3
Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
NCT02224924: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02224924 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 454 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02224924, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two methods that are currently used at the end of a CT guided lung biopsy to close the hole on the surface of the lung in order to minimize the chance of air leaking out of the hole. The two techniques consist of either injecting a very small amount of your the blood called a blood patch into the biopsy hole or injecting a gel-based FDA approved artificial plug called BioSentry that will eventually get absorbed into the body.
Interventions
- OTHER ABPI
- DEVICE BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2014-08-21 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224924
The ClinicalTrials.gov registry entry for NCT02224924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABPI is the first listed.
NCT02224924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224924 about?
NCT02224924 is a clinical study titled "Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures". The purpose of this study is to compare two methods that are currently used at the end of a CT guided lung biopsy to close the hole on the surface of the lung in order to minimize the chance of air leaking out of the hole. The two techniques consist of either injecting a very small amount of your th...
What is the current status of trial NCT02224924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2014-08-21. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT02224924?
The interventions under investigation include: ABPI (OTHER), BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug (DEVICE).
Who is sponsoring clinical trial NCT02224924?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.